IFNα kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model

A major involvement of IFNα in the etiopathogenesis of systemic lupus erythematosus has been suggested by clinical observations, including the increase of serum levels of this cytokine in patients with active disease. Supporting this hypothesis, we have shown that expression of IFNα from a recombinant adenovirus (IFNα Adv) precipitates lupus manifestations in genetically susceptible New Zealand Black (NZB) × New Zealand White (NZW)F1 mice (NZB/W) but not in BALB/c mice. In the present investigation, we have prepared an IFNα immunogen, termed IFNα kinoid, which, appropriately adjuvanted, induces transient neutralizing antibodies (Abs) but no cellular immune response to the cytokine and without apparent side effects. Using this preparation, we also showed that, in kinoid-vaccinated NZB/W mice, lupus manifestations, including proteinuria, histological renal lesions, and death triggered by IFNα Adv challenge were delayed/prevented as long as an effective threshold of anti-IFNα inhibitory capacity was present in the serum.

[1]  D. Isenberg,et al.  Systemic lupus erythematosus. , 2008, The New England journal of medicine.

[2]  S. Della Bella,et al.  Keyhole limpet hemocyanin induces the activation and maturation of human dendritic cells through the involvement of mannose receptor. , 2008, Molecular immunology.

[3]  A. Burny,et al.  Control of allergic reactions in mice by an active anti-murine IL-4 immunization. , 2007, Vaccine.

[4]  B. Ryffel,et al.  VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases , 2007, Proceedings of the National Academy of Sciences.

[5]  Marie-Christophe Boissier,et al.  TNFα kinoid vaccination-induced neutralizing antibodies to TNFα protect mice from autologous TNFα-driven chronic and acute inflammation , 2006, Proceedings of the National Academy of Sciences.

[6]  V. Pascual,et al.  Systemic lupus erythematosus: all roads lead to type I interferons. , 2006, Current opinion in immunology.

[7]  A. Dalloul,et al.  Type-I interferons and systemic lupus erythematosus. , 2006, Autoimmunity reviews.

[8]  L. Rönnblom,et al.  The type I interferon system in systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[9]  L. Mayer,et al.  Monoclonal antibodies, immunogenicity, and associated infusion reactions. , 2005, The Mount Sinai journal of medicine, New York.

[10]  J. Banchereau,et al.  IFN-α Induces Early Lethal Lupus in Preautoimmune (New Zealand Black × New Zealand White)F1 but Not in BALB/c Mice1 , 2005, The Journal of Immunology.

[11]  R. Burnett,et al.  Clinical and histopathological progression of lesions in lupus-prone (NZB x NZW) F1 mice. , 2004, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[12]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[13]  R. Gallo,et al.  Anti-cytokine Ab immune therapy: present status and perspectives. , 2004, Drug discovery today.

[14]  L. Rönnblom,et al.  Expression of the markers BDCA-2 and BDCA-4 and production of interferon-alpha by plasmacytoid dendritic cells in systemic lupus erythematosus. , 2003, Arthritis and rheumatism.

[15]  A. Burny,et al.  Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. , 2003, Cytokine & growth factor reviews.

[16]  T. Stewart.  Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases. , 2003, Cytokine & growth factor reviews.

[17]  Virginia Pascual,et al.  Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.

[18]  D. Choubey,et al.  Type-I Interferon Receptor Deficiency Reduces Lupus-like Disease in NZB Mice , 2003, The Journal of experimental medicine.

[19]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Kourilsky,et al.  Cytokine fields and the polarization of the immune response. , 2001, Trends in immunology.

[21]  A. Burny,et al.  Toward a new generation of vaccines: The anti-cytokine therapeutic vaccines , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  G. Weiner.  The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides , 2000, Journal of leukocyte biology.

[23]  D. Isenberg,et al.  Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. , 2000, Arthritis and rheumatism.

[24]  B. Weill,et al.  FCgammaRII (CD32)-dependent induction of interferon-alpha by serum from patients with lupus erythematosus. , 1999, European cytokine network.

[25]  Z. Bentwich,et al.  Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study). , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[26]  D. Gray,et al.  B-cell memory is short-lived in the absence of antigen. , 1991, Nature.

[27]  D. Remick,et al.  In vivo biologic and immunohistochemical analysis of interleukin-1 alpha, beta and tumor necrosis factor during experimental endotoxemia. Kinetics, Kupffer cell expression, and glucocorticoid effects. , 1991, The American journal of pathology.

[28]  G. Alexander,et al.  Interferon‐α receptor expression and regulation in chronic hepatitis B virus infection , 1991 .

[29]  L. Rönnblom,et al.  Possible induction of systemic lupus erythematosus by interferon‐α treatment in a patient with a malignant carcinoid tumour , 1990, Journal of internal medicine.

[30]  R. Friedman,et al.  Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. , 1982, Science.

[31]  T. Schnitzer,et al.  Serum interferon levels in patients with systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[32]  A. Notkins,et al.  Immune interferon in the circulation of patients with autoimmune disease. , 1979, The New England journal of medicine.

[33]  D. Isenberg,et al.  Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus. , 2008, Handbook of experimental pharmacology.

[34]  L. Pasquier,et al.  Orphanet Journal of Rare Diseases BioMed Central Review , 2006 .

[35]  J. Friedberg.  Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. , 2005, Hematology. American Society of Hematology. Education Program.

[36]  S. Pestka,et al.  A convenient and rapid cytopathic effect inhibition assay for interferon. , 1981, Methods in enzymology.